Tender

Concession for Printing and Marketing of the British Pharmacopoeia

MHRA

This public procurement record has 3 releases in its history.

TenderUpdate

22 Jun 2022 at 10:52

TenderUpdate

13 May 2022 at 15:53

Tender

09 May 2022 at 16:02

Summary of the contracting process

The Medicines and Healthcare Products Regulatory Agency (MHRA) is conducting a tender for the "Concession for Printing and Marketing of the British Pharmacopoeia," which falls under publishing services within the health industry. Located in London, the procurement is currently at the planning stage. Key deadlines include the submission deadline for expressions of interest, which is set for 24 June 2022, and the contract is expected to be awarded in July 2022. This tender will result in a concession contract, whereby the selected organisation will handle the printing, publishing, distribution, marketing, and sale of the British Pharmacopoeia (BP) and British Approved Names (BAN) publications.

This contract presents significant opportunities for businesses engaged in publishing, printing, or marketing services, particularly those with experience in public health or regulatory compliance. Companies specialised in digital services, web design, and distribution logistics would also benefit from this tender, as the selected contractor will be responsible for developing and maintaining a dedicated website for the BP. The contract allows for collaborations with other organisations, providing a platform for firms to leverage their expertise in consortium arrangements, which could facilitate growth and innovation in service delivery and product development within the pharmaceutical sector.

Find more tenders on our Open Data Platform.
How relevant is this notice?

D3 Tenders Premium

Win More Public Sector Contracts

AI-powered tender discovery, pipeline management, and market intelligence — everything you need to grow your public sector business.

Notice Title

Concession for Printing and Marketing of the British Pharmacopoeia

Notice Description

The Medicines and Healthcare products Regulatory Agency (the Agency) is an Executive Agency of the Department of Health. We protect and improve the health of millions of people every day through the effective regulation of medicines and medical devices, underpinned by science and research.The British Pharmacopoeia (BP) is the official collection of standards for UK medicinal products and pharmaceutical substances. It is produced by the British Pharmacopoeia Commission Secretariat of the Medicines and Healthcare Products Regulatory Agency, in accordance with regulation 317(1) of the Human Medicines Regulations 2012, and makes an important contribution to public health by setting publicly available standards for the quality of medicines.The Agency requires the appointment of a Concessionaire to be responsible for the printing, publishing, distribution, marketing and selling of the BP and BAN publications.

Lot Information

Lot 1

The British Pharmacopoeia (BP) is the official collection of standards for UK medicinal products and pharmaceutical substances. It is produced by the British Pharmacopoeia Commission Secretariat of the Medicines and Healthcare Products Regulatory Agency, in accordance with Regulation 317(1) of the Human Medicines Regulations 2012 and makes an important contribution to public health by setting publicly available standards for the quality of medicines.

Since 1864, the BP has been providing authoritative standards for medicinal products and pharmaceutical substances and it continues to play an important role in the standard-setting process worldwide. Now used in over 100 countries, the BP remains an essential reference for all individuals and organisations working within pharmaceutical research and development, manufacture and testing around the globe. All monographs and requirements of the European Pharmacopoeia (Ph. Eur.) are also reproduced in the BP.

The BP is published annually with three in-year updates, currently in both hardcopy and electronic formats; the latter is available as a download product as well as accessed via a single-user licence or a multi-user license arrangement. In addition, there is the requirement for the publication of the British Approved Names (BAN) which provides the official, non-proprietary, or generic names given to pharmaceutical substances, published annually.

The Agency requires the appointment of a concessionaire to be responsible for the printing, publishing, distribution, marketing and selling of the BP and BAN publications. A core part of the requirement is the provision and maintenance of a website, which operates as a portal to access the electronic formats of the BP, as well as acting as a source of added value material and a sales platform for the BP chemical reference standards, orders for which are fulfilled by the Agency. The link to the current website is https://www.pharmacopoeia.com/, and this web address is owned by the Agency. The legacy publication content is available as an XML dataset with a DTD and shall be provided to the service provider.

The concessionaire would have responsibility for business development and marketing of the product, with the strategic approval of the Agency, and also shall be expected to invest in the services to deliver continuous improvement and innovation throughout the life of the contract. The concessionaire will also need to carefully manage sales and distribution of BP publications to our global user base which is currently conducted through established reseller networks.

The Agency wishes to award one concession contract to one contracting party; collaborations with other organisations to bring together the range of expertise (via sub-contracting/consortium arrangements) would be acceptable, with the concessionaire ensuring effective and seamless delivery. The appointed concessionaire shall retain the revenue from the service/sales as its fees minus the payment of agreed royalty fees to the Agency. The concessionaire shall have exclusivity on the sales of the BP and BAN. Pricing strategies shall be reviewed and agreed by both parties. This contracting approach is the same as the current set-up. We expect to award and agree a contract July 2022 to facilitate sufficient lead time for implementation and the publication of the BP2024 in August 2023.

Publication & Lifecycle

Open Contracting ID
ocds-h6vhtk-0335b1
Publication Source
Find A Tender Service
Latest Notice
https://www.find-tender.service.gov.uk/Notice/017029-2022
Current Stage
Tender
All Stages
Tender

Procurement Classification

Notice Type
Tender Notice
Procurement Type
Standard
Procurement Category
Services
Procurement Method
Not Specified
Procurement Method Details
Not specified
Tender Suitability
Not specified
Awardee Scale
Not specified

Common Procurement Vocabulary (CPV)

CPV Divisions

72 - IT services: consulting, software development, Internet and support

79 - Business services: law, marketing, consulting, recruitment, printing and security


CPV Codes

72413000 - World wide web (www) site design services

79342000 - Marketing services

79811000 - Digital printing services

79824000 - Printing and distribution services

79970000 - Publishing services

Notice Value(s)

Tender Value
Not specified
Lots Value
Not specified
Awards Value
Not specified
Contracts Value
Not specified

Notice Dates

Publication Date
22 Jun 20223 years ago
Submission Deadline
23 May 2022Expired
Future Notice Date
Not specified
Award Date
Not specified
Contract Period
Not specified - Not specified
Recurrence
Not specified

Notice Status

Tender Status
Active
Lots Status
Active
Awards Status
Not Specified
Contracts Status
Not Specified

Contracting Authority (Buyer)

Main Buyer
MHRA
Contact Name
Alison Finn
Contact Email
alison.finn@nibsc.org
Contact Phone
+44 7770234628

Buyer Location

Locality
LONDON
Postcode
E14 4PU
Post Town
East London
Country
England

Major Region (ITL 1)
TLI London
Basic Region (ITL 2)
TLI4 Inner London - East
Small Region (ITL 3)
TLI42 Tower Hamlets
Delivery Location
Not specified

Local Authority
Tower Hamlets
Electoral Ward
Canary Wharf
Westminster Constituency
Poplar and Limehouse

Open Contracting Data Standard (OCDS)

View full OCDS Record for this contracting process

Download

The Open Contracting Data Standard (OCDS) is a framework designed to increase transparency and access to public procurement data in the public sector. It is widely used by governments and organisations worldwide to report on procurement processes and contracts.

{
    "tag": [
        "compiled"
    ],
    "id": "ocds-h6vhtk-0335b1-2022-06-22T11:52:53+01:00",
    "date": "2022-06-22T11:52:53+01:00",
    "ocid": "ocds-h6vhtk-0335b1",
    "description": "For Suppliers to participate in the tender exercise for the Concession for Printing and Marketing of the British Pharmacopoeia contract they are required to download a Non Disclosure Agreement (NDA), sign the document and return.<br/><br/>Upon receipt of the signed NDA the Supplier shall be added to the Concession for Printing and Marketing of the British Pharmacopoeia ITT with full access to tender docs.",
    "initiationType": "tender",
    "tender": {
        "id": "ocds-h6vhtk-0335b1",
        "legalBasis": {
            "id": "32014L0023",
            "scheme": "CELEX"
        },
        "title": "Concession for Printing and Marketing of the British Pharmacopoeia",
        "status": "active",
        "classification": {
            "scheme": "CPV",
            "id": "79970000",
            "description": "Publishing services"
        },
        "mainProcurementCategory": "services",
        "description": "The Medicines and Healthcare products Regulatory Agency (the Agency) is an Executive Agency of the Department of Health. We protect and improve the health of millions of people every day through the effective regulation of medicines and medical devices, underpinned by science and research.The British Pharmacopoeia (BP) is the official collection of standards for UK medicinal products and pharmaceutical substances. It is produced by the British Pharmacopoeia Commission Secretariat of the Medicines and Healthcare Products Regulatory Agency, in accordance with regulation 317(1) of the Human Medicines Regulations 2012, and makes an important contribution to public health by setting publicly available standards for the quality of medicines.The Agency requires the appointment of a Concessionaire to be responsible for the printing, publishing, distribution, marketing and selling of the BP and BAN publications.",
        "value": {
            "amount": 0.01,
            "currency": "GBP"
        },
        "lots": [
            {
                "id": "1",
                "description": "The British Pharmacopoeia (BP) is the official collection of standards for UK medicinal products and pharmaceutical substances. It is produced by the British Pharmacopoeia Commission Secretariat of the Medicines and Healthcare Products Regulatory Agency, in accordance with Regulation 317(1) of the Human Medicines Regulations 2012 and makes an important contribution to public health by setting publicly available standards for the quality of medicines.<br/><br/>Since 1864, the BP has been providing authoritative standards for medicinal products and pharmaceutical substances and it continues to play an important role in the standard-setting process worldwide. Now used in over 100 countries, the BP remains an essential reference for all individuals and organisations working within pharmaceutical research and development, manufacture and testing around the globe. All monographs and requirements of the European Pharmacopoeia (Ph. Eur.) are also reproduced in the BP.<br/><br/>The BP is published annually with three in-year updates, currently in both hardcopy and electronic formats; the latter is available as a download product as well as accessed via a single-user licence or a multi-user license arrangement. In addition, there is the requirement for the publication of the British Approved Names (BAN) which provides the official, non-proprietary, or generic names given to pharmaceutical substances, published annually.<br/><br/>The Agency requires the appointment of a concessionaire to be responsible for the printing, publishing, distribution, marketing and selling of the BP and BAN publications. A core part of the requirement is the provision and maintenance of a website, which operates as a portal to access the electronic formats of the BP, as well as acting as a source of added value material and a sales platform for the BP chemical reference standards, orders for which are fulfilled by the Agency. The link to the current website is https://www.pharmacopoeia.com/, and this web address is owned by the Agency. The legacy publication content is available as an XML dataset with a DTD and shall be provided to the service provider.<br/><br/>The concessionaire would have responsibility for business development and marketing of the product, with the strategic approval of the Agency, and also shall be expected to invest in the services to deliver continuous improvement and innovation throughout the life of the contract. The concessionaire will also need to carefully manage sales and distribution of BP publications to our global user base which is currently conducted through established reseller networks.<br/><br/>The Agency wishes to award one concession contract to one contracting party; collaborations with other organisations to bring together the range of expertise (via sub-contracting/consortium arrangements) would be acceptable, with the concessionaire ensuring effective and seamless delivery. The appointed concessionaire shall retain the revenue from the service/sales as its fees minus the payment of agreed royalty fees to the Agency. The concessionaire shall have exclusivity on the sales of the BP and BAN. Pricing strategies shall be reviewed and agreed by both parties. This contracting approach is the same as the current set-up. We expect to award and agree a contract July 2022 to facilitate sufficient lead time for implementation and the publication of the BP2024 in August 2023.",
                "awardCriteria": {
                    "criteria": [
                        {
                            "name": "Selection criteria as stated in the procurement documents"
                        }
                    ]
                },
                "contractPeriod": {
                    "durationInDays": 1800
                },
                "status": "active"
            }
        ],
        "items": [
            {
                "id": "1",
                "additionalClassifications": [
                    {
                        "scheme": "CPV",
                        "id": "79824000",
                        "description": "Printing and distribution services"
                    },
                    {
                        "scheme": "CPV",
                        "id": "72413000",
                        "description": "World wide web (www) site design services"
                    },
                    {
                        "scheme": "CPV",
                        "id": "79342000",
                        "description": "Marketing services"
                    },
                    {
                        "scheme": "CPV",
                        "id": "79811000",
                        "description": "Digital printing services"
                    }
                ],
                "deliveryAddresses": [
                    {
                        "region": "UK"
                    }
                ],
                "relatedLot": "1"
            }
        ],
        "submissionMethod": [
            "electronicSubmission",
            "written"
        ],
        "submissionMethodDetails": "http://health.atamis.co.uk",
        "communication": {
            "atypicalToolUrl": "http://health.atamis.co.uk"
        },
        "documents": [
            {
                "id": "economic",
                "documentType": "economicSelectionCriteria"
            },
            {
                "id": "technical",
                "documentType": "technicalSelectionCriteria"
            }
        ],
        "tenderPeriod": {
            "endDate": "2022-05-23"
        },
        "submissionTerms": {
            "languages": [
                "en"
            ]
        },
        "hasRecurrence": false,
        "amendments": [
            {
                "id": "1",
                "unstructuredChanges": [
                    {
                        "oldValue": {
                            "date": "2022-05-23T12:00:00+01:00"
                        },
                        "newValue": {
                            "date": "2022-06-17T12:00:00+01:00"
                        },
                        "where": {
                            "section": "IV.2.2.1",
                            "label": "Deadline for EOI date"
                        }
                    }
                ]
            },
            {
                "id": "2",
                "unstructuredChanges": [
                    {
                        "oldValue": {
                            "date": "2022-06-17T12:00:00+01:00"
                        },
                        "newValue": {
                            "date": "2022-06-24T12:00:00+01:00"
                        },
                        "where": {
                            "section": "IV.2.7.1",
                            "label": "Tender opening date"
                        }
                    }
                ]
            }
        ]
    },
    "parties": [
        {
            "id": "GB-FTS-16745",
            "name": "MHRA",
            "identifier": {
                "legalName": "MHRA"
            },
            "address": {
                "streetAddress": "10 South Colonnade, Canary Wharf",
                "locality": "London",
                "region": "UKI31",
                "postalCode": "E14 4PU",
                "countryName": "United Kingdom"
            },
            "contactPoint": {
                "name": "Alison Finn",
                "telephone": "+44 7770234628",
                "email": "alison.finn@nibsc.org",
                "url": "http://health.atamis.co.uk"
            },
            "roles": [
                "buyer"
            ],
            "details": {
                "url": "https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency",
                "buyerProfile": "https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency",
                "classifications": [
                    {
                        "scheme": "TED_CA_TYPE",
                        "id": "MINISTRY",
                        "description": "Ministry or any other national or federal authority, including their regional or local subdivisions"
                    },
                    {
                        "scheme": "COFOG",
                        "id": "07",
                        "description": "Health"
                    }
                ]
            }
        },
        {
            "id": "GB-FTS-47339",
            "name": "MHRA/ NIBSC",
            "identifier": {
                "legalName": "MHRA/ NIBSC"
            },
            "address": {
                "streetAddress": "EN6 3QG",
                "locality": "London",
                "postalCode": "EN6 3QG",
                "countryName": "United Kingdom"
            },
            "roles": [
                "reviewBody"
            ],
            "details": {
                "url": "https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency"
            }
        }
    ],
    "buyer": {
        "id": "GB-FTS-16745",
        "name": "MHRA"
    },
    "language": "en"
}